Press Release Prescribing Information
Campath® Alemtuzumab - For Intravenous Use Only
SEARCH
   Home  |  Full Prescribing Information (PDF)  |  Contact Us  |  Site Map  
As a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) - See Things in a Whole New Light: Campath First Line - Campath® Alemtuzumab For Intravenous Use Only
Print | Text Size:

 

Site Map

Home

I Am Taking Campath

About Campath

Side Effects

Administering and Dosing

Caring For Yourself During Treatment

Helping to Manage Side Effects

Avoiding Infections

Rest and Activity

Diet and Nutrition

What to Expect

Education and Resources

Clinical Trials

Questions For Your Doctor

I Am Considering Campath

About Refractory B-CLL

About Campath

Administering and Dosing

Side Effects

What to Expect

Education and Resources

Clinical Trials

Questions For Your Doctor

I Am a Caregiver

About Campath

Side Effects

Administering and Dosing

Caring for the Patient During Treatment

Helping to Manage Side Effects

Avoiding Infections

Rest and Activity

Diet and Nutrition

What to Expect

Education and Resources

Clinical Trials

Questions For Your Doctor

Understanding CLL

Causes, Incidence, and Risk Factors of CLL

Diagnosis of CLL

Blood Tests

Bone Marrow Examination

Cell Markers

Medical Imaging

Staging of CLL

Treatment of CLL

Treatment Response of CLL

Follow-Up Care

References

Resources and Tools

CLL and Cancer Support Links

CLL Tools and Downloads

Campath Reimbursement

Glossary

Questions For Your Doctor

CamCare Assistance Program

Nursing Assistance

Meet Our CamCare Nurses

Full Prescribing Information (PDF)

Contact Us

Privacy Policy

Terms of Use

Indication and Important Safety Information

Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).

WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS

Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)].

Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days [see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)].

Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].

The most commonly reported adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings and Precautions," and "Adverse Reactions" sections of full Prescribing Information.

Please see Full Prescribing Information (PDF).